| |
Article Title |
Author(s) |
Type (Status) |
Available Online |
|
Correlations between serial pro-gastrin-releasing peptide and neuron-specific enolase levels, and the radiological response to treatment and survival of patients with small-cell lung cancer
DOI: 10.1016/j.lungcan.2011.12.012
Abstract: Introduction: To investigate whether decrease in the serum levels of pro-gastrin releasing peptide (ProGRP) and neuron-specific enolase (NSE) were correlated with the radiological response i...
|
Akira Ono,
Tateaki Naito,
Ichiro Ito,
Reiko Watanabe,
Takehito Shukuya,
Hirotsugu Kenmotsu,
Asuka Tsuya,
Yukiko Nakamura,
Haruyasu Murakami,
Kyoichi Kaira,
Toshiaki Takahashi,
Toru Kameya,
Takashi Nakajima,
Masahiro Endo,
Nobuyuki Yamamoto
et al.
|
Full-length article
(In Press Corrected Proof)
|
02 February 2012 |
|
Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trials
DOI: 10.1016/j.lungcan.2012.01.002
Abstract: Background: Socioeconomic status can potentially affect prognosis of cancer patients. Our aim was to describe potential differences in demographic and clinical characteristics, treatment, an...
|
Massimo Di Maio,
Simona Signoriello,
Alessandro Morabito,
Antonio Rossi,
Paolo Maione,
FrancoVito Piantedosi,
Domenico Bilancia,
Silvio Cigolari,
Santi Barbera,
Vittorio Gebbia,
Bruno Daniele,
Sergio Federico Robbiati,
Alfonso Illiano,
Anna Ceribelli,
Francesco Carrozza,
Adolfo Favaretto,
Elena Piazza,
Maria Carmela Piccirillo,
Gennaro Daniele,
Pasqualina Giordano,
Raffaele Costanzo,
Claudia Sandomenico,
Gaetano Rocco,
Ciro Gallo,
Francesco Perrone,
Cesare Gridelli
et al.
|
Full-length article
(In Press Corrected Proof)
|
02 February 2012 |
|
Stromal CD4/CD25 positive T-cells are a strong and independent prognostic factor in non-small cell lung cancer patients, especially with adenocarcinomas
DOI: 10.1016/j.lungcan.2012.01.004
Abstract: Within the concert of immune reactions against tumour cells cytotoxic and regulatory T-cells are of utmost importance. Several studies revealed contradictory results on this issue. We theref...
|
Gian Kayser,
Luzie Schulte-Uentrop,
Wulf Sienel,
Martin Werner,
Paul Fisch,
Bernward Passlick,
Axel zur Hausen,
Christian Stremmel
et al.
|
Full-length article
(In Press Corrected Proof)
|
02 February 2012 |
|
Stereotactic body radiotherapy (SBRT) for solitary pulmonary nodules clinically diagnosed as lung cancer with no pathological confirmation: Comparison with non-small-cell lung cancer
DOI: 10.1016/j.lungcan.2012.01.006
Abstract: Introduction: In non-surgical candidates with solitary pulmonary nodules (SPNs) and no histological confirmation, optimal management remains uncertain. Methods: Between February 2005 and Feb...
|
Atsuya Takeda,
Etsuo Kunieda,
Naoko Sanuki,
Yousuke Aoki,
Yohei Oku,
Hiroshi Handa
et al.
|
Full-length article
(In Press Corrected Proof)
|
02 February 2012 |
|
When will I get my breath back? Recovery time of exercise-induced breathlessness in patients with thoracic cancer
DOI: 10.1016/j.lungcan.2012.01.003
Breathlessness is a common symptom in thoracic cancer. It impacts adversely on physical activity levels and the resultant deconditioning may exacerbate the decline in physical capacity . Therapeutic e...
|
Matthew Maddocks,
Victoria Taylor,
Radka Klezlova,
Ruth England,
Cathann Manderson,
Andrew Wilcock
et al.
|
Correspondence
(In Press Corrected Proof)
|
30 January 2012 |
|
Prognostic impact of the primary tumor location based on the hilar structures in non-small cell lung cancer with mediastinal lymph node metastasis
DOI: 10.1016/j.lungcan.2011.07.015
Abstract: The status of mediastinal lymph node metastasis is one of the main factors determining the treatment strategy for non-small cell lung cancer (NSCLC), but the primary tumor location is not co...
|
Masaoki Ito,
Yoshinori Yamashita,
Yoshihiro Miyata,
Masahiro Ohara,
Yasuhiro Tsutani,
Takuhiro Ikeda,
Keizo Misumi,
Hiroaki Harada,
Ken-ichi Omori
et al.
|
Full-length article
(In Press Corrected Proof)
|
30 January 2012 |
|
Verification of beam delivery using fibrosis after proton beam irradiation to the lung tumor
DOI: 10.1016/j.lungcan.2012.01.007
Abstract: Background and purpose: To investigate the geometrical accuracy in proton beam therapy (PBT) to the lung by comparing the location of the fibrosis after PBT and the tumor using less invasive...
|
Nobuyoshi Fukumitsu,
Yoshiko Oshiro,
Takayuki Hashimoto,
Toshiyuki Okumura,
Masashi Mizumoto,
Takashi Moritake,
Koji Tsuboi,
Takeji Sakae,
Hideyuki Sakurai
et al.
|
Full-length article
(In Press Corrected Proof)
|
27 January 2012 |
|
EGFR–TKI resistant non-small cell lung cancer (NSCLC): New developments and implications for future treatment
DOI: 10.1016/j.lungcan.2011.12.014
Abstract: Treatment with receptor-tyrosine kinase inhibitors (TKIs) has improved progression-free and overall survival in patients with advanced non-small cell lung cancer (NSCLC). One major target fo...
|
Wolfram Brugger,
Michael Thomas
|
Review article
(In Press Corrected Proof)
|
27 January 2012 |
|
Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: Study-level and patient-level meta-analyses
DOI: 10.1016/j.lungcan.2011.12.015
Abstract: In anemic patients receiving myelosuppressive chemotherapy, erythropoiesis-stimulating agents (ESAs) raise hemoglobin levels and reduce transfusion requirements, but ESA-related safety conce...
|
Johan Vansteenkiste,
John Glaspy,
David Henry,
Heinz Ludwig,
Robert Pirker,
Dianne Tomita,
Helen Collins,
Jeffrey Crawford
et al.
|
Full-length article
(In Press Corrected Proof)
|
25 January 2012 |
|
Maintenance treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology
DOI: 10.1016/j.lungcan.2011.12.011
Abstract: Several randomized trials have recently investigated the role of maintenance treatment for patients with advanced non-small-cell lung cancer (NSCLC) with responding or stable disease after c...
|
Cesare Gridelli,
Filippo de Marinis,
Massimo Di Maio,
Andrea Ardizzoni,
Chandra P. Belani,
Federico Cappuzzo,
Fortunato Ciardiello,
Panagiotis Fidias,
Luis Paz-Ares,
Francesco Perrone,
Robert Pirker,
Luigi De Petris,
Rolf Stahel
et al.
|
Review article
(In Press Corrected Proof)
|
24 January 2012 |
|
Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab
DOI: 10.1016/j.lungcan.2011.12.006
Abstract: Background: The impact of age on prognosis in advanced stage non-small cell lung cancer (NSCLC) may differ by sex. Patients and methods: Eligible patients (N=1590) from E1594, a 4-arm platin...
|
H.A. Wakelee,
S.E. Dahlberg,
J.R. Brahmer,
J.H. Schiller,
M.C. Perry,
C.J. Langer,
A.B. Sandler,
C.P. Belani,
D.H. Johnson,
Eastern Cooperative Oncology Group
et al.
|
Full-length article
(In Press Corrected Proof)
|
24 January 2012 |
|
In situ detection of lung cancer volatile fingerprints using bronchoscopic air-sampling
DOI: 10.1016/j.lungcan.2011.12.010
Abstract: Lung cancer diagnosis via breath analysis has to overcome some issues that can be summarized by two crucial points: (1) further developments for more performant breath sampling technologies;...
|
M. Santonico,
G. Lucantoni,
G. Pennazza,
R. Capuano,
G. Galluccio,
C. Roscioni,
G. La Delfa,
D. Consoli,
E. Martinelli,
R. Paolesse,
C. Di Natale,
A. D’Amico
et al.
|
Full-length article
(In Press Corrected Proof)
|
20 January 2012 |
|
Inhibitory effect of riccardin D on growth of human non-small cell lung cancer: In vitro and in vivo studies
DOI: 10.1016/j.lungcan.2011.12.013
Abstract: Riccardin D is a macrocyclic bisbibenzyl compound extracted from liverwort plant Dumortiera hirsuta. Our previous study showed that riccardin D induced apoptosis of human leukemia cells by t...
|
Xia Xue,
De-Fu Sun,
Cui-Cui Sun,
Hui-Ping Liu,
Bin Yue,
Cui-Rong Zhao,
Hong-Xiang Lou,
Xian-Jun Qu
et al.
|
Full-length article
(In Press Corrected Proof)
|
19 January 2012 |
|
An ectopic ACTH-producing small cell lung carcinoma associated with enhanced corticosteroid biosynthesis in the peritumoral areas of adrenal metastasis
DOI: 10.1016/j.lungcan.2011.12.007
Abstract: A 60-year-old Japanese male presented with swelling of bilateral cervical lymph nodes was subsequently diagnosed as the late stage of primary small cell lung carcinoma (SCLC). He was then tr...
|
Hironori Satoh,
Ryoko Saito,
Shu Hisata,
Jun Shiihara,
Shinji Taniuchi,
Yasuhiro Nakamura,
Toshihiro Nukiwa,
Masahito Ebina,
Hironobu Sasano
et al.
|
Full-length article
(In Press Corrected Proof)
|
17 January 2012 |
|
Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer
DOI: 10.1016/j.lungcan.2011.12.005
Abstract: Purpose: This multicenter, randomized, open-label, phase II study (JO19907) compared the efficacy and safety of first-line carboplatin-paclitaxel (CP) alone with bevacizumab-CP in Japanese p...
|
Seiji Niho,
Hideo Kunitoh,
Hiroshi Nokihara,
Takeshi Horai,
Yukito Ichinose,
Toyoaki Hida,
Nobuyuki Yamamoto,
Masaaki Kawahara,
Tetsu Shinkai,
Kazuhiko Nakagawa,
Kaoru Matsui,
Shunichi Negoro,
Akira Yokoyama,
Shinzoh Kudoh,
Katsuyuki Kiura,
Kiyoshi Mori,
Hiroaki Okamoto,
Hiroshi Sakai,
Koji Takeda,
Soichiro Yokota,
Nagahiro Saijo,
Masahiro Fukuoka,
JO19907 Study Group
et al.
|
Full-length article
(In Press Corrected Proof)
|
16 January 2012 |
|
Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: An harmful procedure
DOI: 10.1016/j.lungcan.2011.12.009
Abstract: The effects on long-term post-operative quality of life (QoL) and disease-control in malignant pleural mesothelioma (MPM) of extrapleural pneumonectomy (EPP) and pleurectomy/decortication (P...
|
Ottavio Rena,
Caterina Casadio
|
Full-length article
(In Press Corrected Proof)
|
13 January 2012 |
|
MO19390 (SAiL): Bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC
DOI: 10.1016/j.lungcan.2011.11.020
Abstract: Introduction: The clinical benefit and safety profile associated with first-line bevacizumab with doublet chemotherapy in patients with advanced non-squamous non-small cell lung cancer (NSCL...
|
Eric Dansin,
Saverio Cinieri,
Pilar Garrido,
Frank Griesinger,
Dolores Isla,
Manfred Koehler,
Martin Kohlhaeufl
et al.
|
Full-length article
(In Press Corrected Proof)
|
12 January 2012 |
|
Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma
DOI: 10.1016/j.lungcan.2011.12.004
Abstract: Background: The overexpression of receptor tyrosine kinase EphA2 has been reported in various cancers. In non-small cell lung cancer (NSCLC), a positive correlation has been reported between...
|
Masashi Ishikawa,
Ryo Miyahara,
Makoto Sonobe,
Marika Horiuchi,
Toshi Mennju,
Ei Nakayama,
Masashi Kobayashi,
Ryutaro Kikuchi,
Jiro Kitamura,
Naoto Imamura,
Cheng-Long Huang,
Hiroshi Date
et al.
|
Full-length article
(In Press Corrected Proof)
|
11 January 2012 |
|
History of tuberculosis as an independent prognostic factor for lung cancer survival
DOI: 10.1016/j.lungcan.2011.12.008
Abstract: Introduction: It is well known that pulmonary tuberculosis is associated with an increased risk of lung cancer. We investigated whether a history of pulmonary tuberculosis is an independent ...
|
Marlies E. Heuvers,
Joachim G.J.V. Aerts,
Joost P. Hegmans,
Joris D. Veltman,
André G. Uitterlinden,
Rikje Ruiter,
Eline M. Rodenburg,
Albert Hofman,
Marleen Bakker,
Henk C. Hoogsteden,
Bruno H. Stricker,
Rob J. van Klaveren
et al.
|
Full-length article
(In Press Corrected Proof)
|
09 January 2012 |
|
Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: A real-world cost-effectiveness analysis
DOI: 10.1016/j.lungcan.2011.12.003
Abstract: Erlotinib has been approved as a third-line treatment for advanced non-small-cell lung cancer (NSCLC) in British Columbia (BC). A cost-effectiveness analysis was conducted to compare costs a...
|
Ian Cromwell,
Kimberly van der Hoek,
Suzanne C. Malfair Taylor,
Barbara Melosky,
Stuart Peacock
et al.
|
Full-length article
(In Press Corrected Proof)
|
09 January 2012 |
|
Challenges scoring radiation pneumonitis in patients irradiated for lung cancer
DOI: 10.1016/j.lungcan.2011.11.025
Abstract: Background and purpose: To quantify uncertainties in scoring radiation pneumonitis. Materials and methods: Records of 434 patients irradiated for lung cancer from 2000 to 2010 were retrospec...
|
Eda Yirmibesoglu,
Daniel S. Higginson,
Merdan Fayda,
M. Patricia Rivera,
Jan Halle,
Julian Rosenman,
Liyi Xie,
Lawrence B. Marks
et al.
|
Full-length article
(In Press Corrected Proof)
|
09 January 2012 |
|
A meta-analysis of paclitaxel-based chemotherapies administered once every week compared with once every 3 weeks first-line treatment of advanced non-small-cell lung cancer
DOI: 10.1016/j.lungcan.2011.12.001
Abstract: Objective: The published data on the curative effects of comparing the once weekly paclitaxel-based chemotherapies (W-paclitaxel) with the standard every 3 weeks paclitaxel-based chemotherap...
|
Guanghui Gao,
Haiqing Chu,
Lan Zhao,
Tao Gui,
Qinghua Xu,
Jianping Shi
et al.
|
Full-length article
(In Press Corrected Proof)
|
09 January 2012 |
|
Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer
DOI: 10.1016/j.lungcan.2011.10.018
Abstract: Circulating tumour cells (CTCs) have attracted much recent interest in cancer research as a potential biomarker and as a means of studying the process of metastasis. It has long been underst...
|
John D. O’Flaherty,
Steven Gray,
Derek Richard,
Dean Fennell,
John J. O’Leary,
Fiona H. Blackhall,
Kenneth J. O’Byrne
et al.
|
Review article
(In Press Corrected Proof)
|
03 January 2012 |
|
Clonality status of multifocal lung adenocarcinomas based on the mutation patterns of EGFR and K-ras
DOI: 10.1016/j.lungcan.2011.08.007
Abstract: Purpose: The purpose of this study is to clarify the clonality status of multifocal lung adenocarcinomas based on the mutation patterns of epidermal growth factor receptor (EGFR) and K-ras. ...
|
Kazuya Takamochi,
Shiaki Oh,
Joe Matsuoka,
Kenji Suzuki
|
Full-length article
(In Press Corrected Proof)
|
30 December 2011 |
|
The management impact of clinically significant incidental lesions detected on staging FDG PET-CT in patients with non-small cell lung cancer (NSCLC): An analysis of 649 cases
DOI: 10.1016/j.lungcan.2011.11.024
Abstract: To evaluate FDG PET-CT in the detection of unexpected pre-malignancy or second malignancy at the initial staging of patients with histologically proven non-small cell lung cancer (NSCLC) and...
|
Michael Lin,
Chaitanya Ambati
|
Full-length article
(In Press Corrected Proof)
|
29 December 2011 |
|
Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum
DOI: 10.1016/j.lungcan.2011.12.002
Abstract: Background: Previous studies in sarcoma found that a composite gene signature, including high expression of nucleotide excision repair (NER) genes (XPG and/or ERCC1) and low expression of ho...
|
Bartomeu Massuti,
Manuel Cobo,
Carlos Camps,
Manuel Dómine,
Mariano Provencio,
Vicente Alberola,
Nuria Viñolas,
Rafael Rosell,
Miguel Tarón,
Vanesa Gutiérrez-Calderón,
Pilar Lardelli,
Vicente Alfaro,
Antonio Nieto,
Dolores Isla
et al.
|
Full-length article
(In Press Corrected Proof)
|
26 December 2011 |
|
Characteristics of lung cancer in women: Importance of hormonal and growth factors
DOI: 10.1016/j.lungcan.2011.11.023
Abstract: Based on epidemiological, clinical, and preclinical data, lung carcinogenesis can be distinctive in women, suggesting that women should be treated differently depending on the expression of ...
|
Isabelle Rouquette,
Valérie Lauwers-Cances,
Camille Allera,
Laurent Brouchet,
Julie Milia,
Yvan Nicaise,
Julie Laurent,
Marie-Bernadette Delisle,
Gilles Favre,
Alain Didier,
Julien Mazières
et al.
|
Full-length article
(In Press Corrected Proof)
|
26 December 2011 |
|
Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107)
DOI: 10.1016/j.lungcan.2011.11.014
Abstract: Introduction: The Cancer and Leukemia Group B (CALGB) conducted a multi-center phase II trial to evaluate the efficacy and safety of vatalanib in previously untreated patients with malignant...
|
Thierry Jahan,
Lin Gu,
Robert Kratzke,
Arkadiusz Dudek,
Gregory A. Otterson,
Xiaofei Wang,
Mark Green,
Everett E. Vokes,
Hedy Lee Kindler
et al.
|
Full-length article
(In Press Corrected Proof)
|
26 December 2011 |
|
Prospective phase II trial of a combination of gemcitabine and UFT as first-line treatment in elderly patients with advanced non-small cell lung cancer
DOI: 10.1016/j.lungcan.2011.11.021
Abstract: Background: The standard regimen in elderly patients with non-small-cell lung cancer (NSCLC) is still uncertain. Gemcitabine is one of the most widely used drugs for the treatment of NSCLC, ...
|
Jin Ho Baek,
Hawk Kim,
Jong-Joon Ahn,
Yangjin Jegal,
Kwang Won Seo,
Seung Won Ra,
Chang Ryul Park,
Jong Pil Jung,
Jeong Won Kim,
Yong Jik Lee,
Hee Jeong Cha,
Woon Jung Kwon,
Young Ju Noh,
Sukjoong Oh,
Jae-Hoo Park,
Young Joo Min
et al.
|
Full-length article
(In Press Corrected Proof)
|
22 December 2011 |
|
Small-cell carcinoma of the lung detected by CT screening: Stage distribution and curability
DOI: 10.1016/j.lungcan.2011.11.017
Abstract: Background: Prognosis is incompletely known for small-cell lung carcinoma (SCLC) detected by CT screening of at-risk subjects. Methods: A multinational study of baseline and annual repeat CT...
|
John H.M. Austin,
Rowena Yip,
Belinda M. D'Souza,
David F. Yankelevitz,
Claudia I. Henschke,
for the International Early Lung Cancer Action Program Investigators
et al.
|
Full-length article
(In Press Corrected Proof)
|
22 December 2011 |
|
Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era
DOI: 10.1016/j.lungcan.2011.11.022
Abstract: Background: We analyzed the patterns of treatment and clinical outcomes of leptomeningeal metastasis (LM) in patients with non-small cell lung cancer (NSCLC) in the modern chemotherapy era. ...
|
Jin Hyun Park,
Yu Jung Kim,
Jeong-Ok Lee,
Keun-Wook Lee,
Jee Hyun Kim,
Soo-Mee Bang,
Jin-Haeng Chung,
Jae Sung Kim,
Jong Seok Lee
et al.
|
Full-length article
(In Press Corrected Proof)
|
20 December 2011 |
|
CHD5, a tumor suppressor that is epigenetically silenced in lung cancer
DOI: 10.1016/j.lungcan.2011.11.019
Abstract: Chromodomain helicase DNA binding protein 5 (CHD5) is a potent tumor suppressor that serves as a master regulator of a tumor-suppressive network. Examination of the role played by CHD5 in a ...
|
Rui Zhao,
Qitao Yan,
Jingye Lv,
Haili Huang,
Wenling Zheng,
Bao Zhang,
Wenli Ma
et al.
|
Full-length article
(In Press Corrected Proof)
|
20 December 2011 |
|
Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer
DOI: 10.1016/j.lungcan.2011.09.006
Abstract: Background: Preliminary results indicated that bortezomib (B) (Velcade*) as a single agent may have activity in pretreated NSCLC patients with similar or lesser toxicity compared to chemothe...
|
Benjamin Besse,
David Planchard,
Anne-Sophie Veillard,
Laurent Taillade,
David Khayat,
Muriel Ducourtieux,
Jean-Pierre Pignon,
Jean Lumbroso,
Carole Lafontaine,
Claire Mathiot,
Jean-Charles Soria
et al.
|
Full-length article
(In Press Corrected Proof)
|
20 December 2011 |
|
Estimation of renal function in lung cancer patients
DOI: 10.1016/j.lungcan.2011.11.016
Abstract: Introduction: In lung cancer patients treated with chemotherapy, renal function is an important parameter to be monitored. Since measurement of renal function with either isotope or creatini...
|
Katja Trobec,
Lea Knez,
Pika Meško Brguljan,
Tanja Cufer,
Mitja Lainščak
et al.
|
Full-length article
(In Press Corrected Proof)
|
19 December 2011 |
|
Soluble epidermal growth factor receptor isoforms in non-small cell lung cancer tissue and in blood
DOI: 10.1016/j.lungcan.2011.11.018
Abstract: Epidermal growth factor receptor (EGFR) is implicated in tumor development and is highly expressed in many human tumors. EGFR overexpression has been observed in both premalignant lesions an...
|
Sally Maramotti,
Massimiliano Paci,
Francesca Miccichè,
Alessia Ciarrocchi,
Alberto Cavazza,
Maida De Bortoli,
Elena Vaghi,
Debora Formisano,
Laura Canovi,
Giorgio Sgarbi,
Italia Bongarzone
et al.
|
Full-length article
(In Press Corrected Proof)
|
19 December 2011 |
|
Biomarkers for small cell lung cancer: Neuroendocrine, epithelial and circulating tumour cells
DOI: 10.1016/j.lungcan.2011.11.015
Abstract: Small cell lung cancer (SCLC) is characterised by an aggressive clinical course with invariable resistance to chemotherapy despite initially high response rates. There has been little improv...
|
Rachel Stovold,
Fiona Blackhall,
Suzanne Meredith,
JianMei Hou,
Caroline Dive,
Anne White
et al.
|
Review article
(In Press Corrected Proof)
|
19 December 2011 |
|
The role of molecular analyses in the era of personalized therapy for advanced NSCLC
DOI: 10.1016/j.lungcan.2011.11.013
Abstract: Platinum-based doublet chemotherapy is the traditional treatment of choice for advanced non-small cell lung cancer (NSCLC); however, the efficacy of these regimens has reached a plateau. Inc...
|
Nichole T. Tanner,
Nicholas J. Pastis,
Carol Sherman,
George R. Simon,
David Lewin,
Gerard A. Silvestri
et al.
|
Review article
(In Press Corrected Proof)
|
16 December 2011 |
|
Parity and risk of lung cancer in women: Systematic review and meta-analysis of epidemiological studies
DOI: 10.1016/j.lungcan.2011.10.014
Abstract: Multiple studies have assessed parity as a risk factor for lung cancer but results have been inconclusive. We searched MEDLINE (through August 2010) and the Institute of Scientific Informati...
|
Issa J. Dahabreh,
Thomas A. Trikalinos,
Jessica K. Paulus
|
Full-length article
(In Press Corrected Proof)
|
12 December 2011 |
|
Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: A comprehensive study of Caucasian non-smokers
DOI: 10.1016/j.lungcan.2011.11.004
Abstract: EML4-ALK adenocarcinomas constitute a new molecular subgroup of lung tumours that respond very well to crizotinib, an ALK inhibitor. However, the diagnosis of ALK rearrangement in lung cance...
|
Pierre-Alexandre Just,
Aurélie Cazes,
Anne Audebourg,
Anatole Cessot,
Karine Pallier,
Claire Danel,
Marie-Cécile Vacher-Lavenu,
Pierre Laurent-Puig,
Benoît Terris,
Hélène Blons
et al.
|
Full-length article
(In Press Corrected Proof)
|
08 December 2011 |
|
Differences in metabolism between adeno- and squamous cell non-small cell lung carcinomas: Spatial distribution and prognostic value of GLUT1 and MCT4
DOI: 10.1016/j.lungcan.2011.11.006
Abstract: Background: Hypoxia leads to changes in tumor cell metabolism such as increased glycolysis. In this study, we examined the spatial distribution of the glycolysis and hypoxia related markers ...
|
Tineke W.H. Meijer,
Olga C.J. Schuurbiers,
Johannes H.A.M. Kaanders,
Monika G. Looijen-Salamon,
Lioe-Fee de Geus-Oei,
Ad F.T.M. Verhagen,
Jasper Lok,
Henricus F.M. van der Heijden,
Saskia E. Rademakers,
Paul N. Span,
Johan Bussink
et al.
|
Full-length article
(In Press Corrected Proof)
|
08 December 2011 |
|
Carcinoembryonic antigen (CEA) as tumor marker in lung cancer
DOI: 10.1016/j.lungcan.2011.11.012
Abstract: The use of CEA as a prognostic and predictive marker in patients with lung cancer is widely debated. The aim of this review was to evaluate the results from studies made on this subject. Usi...
|
M. Grunnet,
J.B. Sorensen
|
Review article
(In Press Corrected Proof)
|
08 December 2011 |
|
Characterization of the immunophenotype of the tumor budding and its prognostic implications in squamous cell carcinoma of the lung
DOI: 10.1016/j.lungcan.2011.11.010
Abstract: Tumor budding is morphologically defined as infiltration by small clusters of cancer cells. While the biological properties of budding cells in adenocarcinoma (decreased expression of adhesi...
|
Tetsuhiko Taira,
Genichiro Ishii,
Kanji Nagai,
Kiyotaka Yoh,
Yusuke Takahashi,
Yuki Matsumura,
Motohiro Kojima,
Hironobu Ohmatsu,
Koichi Goto,
Seiji Niho,
Hiroshi Takashima,
Hiromasa Inoue,
Yuichiro Ohe,
Atsushi Ochiai
et al.
|
Full-length article
(In Press Corrected Proof)
|
08 December 2011 |
|
A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer
DOI: 10.1016/j.lungcan.2011.11.005
Abstract: Erlotinib and pemetrexed were approved by the European Medicines Agency for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC...
|
Mark J.C. Nuijten,
Javier de Castro Carpeño,
Christos Chouaid,
Alain Vergnenègre,
Francesco Grossi,
Helge Bischoff,
David Heigener,
Stefan Walzer
et al.
|
Full-length article
(In Press Corrected Proof)
|
07 December 2011 |
|
The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group
DOI: 10.1016/j.lungcan.2011.10.017
Highlights: ► The diagnosis of lung cancer involves the identification and complete classification of malignancy. ► New therapeutic options require specific subtyping of NSCLCs and, increasingly, the ...
|
Erik Thunnissen,
Keith M. Kerr,
Felix J.F. Herth,
Sylvie Lantuejoul,
Mauro Papotti,
Robert C. Rintoul,
Giulio Rossi,
Birgit G. Skov,
Birgit Weynand,
Lukas Bubendorf,
Grünberg Katrien,
Leif Johansson,
Fernando López-Ríos,
Vincent Ninane,
Włodzimierz Olszewski,
Helmut Popper,
Sauleda Jaume,
Philipp Schnabel,
Luc Thiberville,
Florian Laenger
et al.
|
Review article
(In Press Corrected Proof)
|
06 December 2011 |
|
FATS expression is associated with cisplatin sensitivity in non small cell lung cancer
DOI: 10.1016/j.lungcan.2011.11.009
Abstract: Background: Although the survival benefit of cisplatin-based adjuvant chemotherapy has been proven for patients with non small cell lung cancer (NSCLC), the resistance to cisplatin and its d...
|
Yin Tian,
Jun Zhang,
Shuangshuang Yan,
Li Qiu,
Zheng Li
et al.
|
Full-length article
(In Press Corrected Proof)
|
05 December 2011 |
|
Conversion from the “oncogene addiction” to “drug addiction” by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation
DOI: 10.1016/j.lungcan.2011.11.007
Abstract: Emergence of acquired resistance is virtually inevitable in patients with a mutation in the epidermal growth factor receptor gene (EGFR) treated with EGFR tyrosine kinase inhibitors (TKIs). ...
|
Kenichi Suda,
Kenji Tomizawa,
Hirotaka Osada,
Yoshihiko Maehara,
Yasushi Yatabe,
Yoshitaka Sekido,
Tetsuya Mitsudomi
et al.
|
Full-length article
(In Press Corrected Proof)
|
02 December 2011 |
|
Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: A proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma
DOI: 10.1016/j.lungcan.2011.11.008
Abstract: Background: To characterize the clinicopathologic features of ALK-rearranged lung cancer, and suggest a molecular test protocol for lung adenocarcinoma in the small biopsy specimen. Methods:...
|
Jin Ho Paik,
Chang-Min Choi,
Hyojin Kim,
Se Jin Jang,
Gheeyoung Choe,
Dong Kwan Kim,
Hwa Jung Kim,
Hoil Yoon,
Choon-Taek Lee,
Sanghoon Jheon,
Ji-Young Choe,
Jin-Haeng Chung
et al.
|
Full-length article
(In Press Corrected Proof)
|
02 December 2011 |
|
Mesothelioma and lung cancer mortality: A historical cohort study among asbestosis workers in Hong Kong
DOI: 10.1016/j.lungcan.2011.11.003
Abstract: Objectives: To investigate the mortality pattern among a cohort of workers with asbestosis in Hong Kong, with special emphases on mesothelioma and lung cancer. Methods: All 124 male workers ...
|
Minghui Chen,
Lap Ah Tse,
Ronald K.F. Au,
Ignatius T.S. Yu,
Xiao-rong Wang,
Xiang-qian Lao,
Joseph Siu-kei Au
et al.
|
Full-length article
(In Press Corrected Proof)
|
02 December 2011 |
|
Risk of lung cancer by histology among immigrants to Sweden
DOI: 10.1016/j.lungcan.2011.10.022
Abstract: Background: We wanted to define lung cancer incidence rates by histological subtype among immigrants in Sweden to explore the effect of new environments on the incidence of lung cancer by hi...
|
Seyed Mohsen Mousavi,
Kristina Sundquist,
Kari Hemminki
|
Full-length article
(In Press Corrected Proof)
|
24 November 2011 |
|
Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): A combined analysis of three phase 3 trials
DOI: 10.1016/j.lungcan.2011.10.021
Abstract: Introduction: In a first-line study of advanced NSCLC, pemetrexed–cisplatin was more effective among patients with adenocarcinoma and large-cell carcinoma compared with gemcitabine–cisplatin...
|
Joseph Treat,
Giorgio V. Scagliotti,
Guangbin Peng,
Matthew J. Monberg,
Coleman K. Obasaju,
Mark A. Socinski
et al.
|
Full-length article
(In Press Corrected Proof)
|
24 November 2011 |
|
Hedgehog signaling pathway molecules and ALDH1A1 expression in early-stage non-small cell lung cancer
DOI: 10.1016/j.lungcan.2011.10.015
Abstract: Introduction: The Hedgehog Signaling Pathway (HHSP) has been implicated in the development of multiple cancers. HHSP activation may primarily be hedgehog ligand-dependent in non-small cell l...
|
Guy Raz,
Kristi E. Allen,
Chris Kingsley,
Irene Cherni,
Shilpi Arora,
Aprill Watanabe,
Carlos D. Lorenzo,
David K. Edwards V,
Shravan Sridhar,
Galen Hostetter,
Glen J. Weiss
et al.
|
Full-length article
(In Press Corrected Proof)
|
24 November 2011 |
|
Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer
DOI: 10.1016/j.lungcan.2011.10.009
Abstract: Background: To investigate the prognostic importance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer (NSCLC). Patients and methods: Using ...
|
Lee W. Jones,
Whitney E. Hornsby,
Amy Goetzinger,
Lindsay M. Forbes,
Emily L. Sherrard,
Morten Quist,
Amy T. Lane,
Miranda West,
Neil D. Eves,
Margaret Gradison,
April Coan,
James E. Herndon,
Amy P. Abernethy
et al.
|
Full-length article
(In Press Corrected Proof)
|
23 November 2011 |
|
Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies
DOI: 10.1016/j.lungcan.2011.10.023
Abstract: Icotinib, one of the leading compounds selected from our compound library, was found to be a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with ...
|
Fenlai Tan,
Xiaoyan Shen,
Dechang Wang,
Guojian Xie,
Xiaodong Zhang,
Lieming Ding,
Yunyan Hu,
Wei He,
Yanping Wang,
Yinxiang Wang
et al.
|
Full-length article
(In Press Corrected Proof)
|
23 November 2011 |
|
Fasting blood glucose level and prognosis in non-small cell lung cancer (NSCLC) patients
DOI: 10.1016/j.lungcan.2011.10.019
Abstract: Diabetes has been consistently linked to many forms of cancers, such as liver, colorectal, pancreatic, and breast cancer, however, the role of diabetes in outcome among cancer patients remai...
|
Juhua Luo,
Yea-Jyh Chen,
Li-Jung Chang
|
Full-length article
(In Press Corrected Proof)
|
23 November 2011 |
|
Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer
DOI: 10.1016/j.lungcan.2011.10.020
Abstract: To define the pathological features associated with response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in NSCLC, we have evaluated tumor histopathological ...
|
Humberto Lara-Guerra,
Catherine T. Chung,
Joerg Schwock,
Melania Pintilie,
David M. Hwang,
Natasha B. Leighl,
Thomas K. Waddell,
Ming-Sound Tsao
et al.
|
Full-length article
(In Press Corrected Proof)
|
23 November 2011 |
|
Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature
DOI: 10.1016/j.lungcan.2011.10.008
Abstract: Introduction: Erlotinib is an agent in the class of oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Although this class of agents is considered to be relatively safe...
|
R. ter Heine,
R.T.A. van den Bosch,
C.M. Schaefer-Prokop,
N.A.G. Lankheet,
J.H. Beijnen,
G.H.A. Staaks,
M.M. van der Westerlaken,
M.M. Malingré,
J.J.G. van den Brand
et al.
|
Review article
(In Press Corrected Proof)
|
21 November 2011 |
|
Lipid MALDI profile classifies non-small cell lung cancers according to the histologic type
DOI: 10.1016/j.lungcan.2011.10.016
Abstract: We investigated whether direct tissue matrix-assisted laser desorption/ionization (MALDI) mass spectrometry (MS) analysis on lipid may assist with the histopathologic diagnosis of non-small ...
|
Geon Kook Lee,
Hee Seok Lee,
Young Seung Park,
Jeong Hwa Lee,
Seok Cheol Lee,
Jong Ho Lee,
Soo Jae Lee,
Selina Rahman Shanta,
Hye Min Park,
Hyo Rim Kim,
In Hoo Kim,
Young Hwan Kim,
Jae Ill Zo,
Kwang Pyo Kim,
Hark Kyun Kim
et al.
|
Full-length article
(In Press Corrected Proof)
|
18 November 2011 |
|
Factors associated with smoking abstinence among smokers and recent-quitters with lung and head and neck cancer
DOI: 10.1016/j.lungcan.2011.10.005
Abstract: Introduction: Smoking cessation among cancer patients is critical for improving outcomes. Understanding factors associated with smoking abstinence after the diagnosis of cancer can provide d...
|
Mary E. Cooley,
Qian Wang,
Bruce E. Johnson,
Paul Catalano,
Robert I. Haddad,
Raphael Bueno,
Karen M. Emmons
et al.
|
Full-length article
(In Press Corrected Proof)
|
17 November 2011 |
|
Immunosuppression and lung cancer of donor origin after bilateral lung transplantation
DOI: 10.1016/j.lungcan.2011.10.001
Abstract: Analysis of databases from transplant recipients revealed a 3–5 fold higher risk to develop de novo malignancies under continued immunosuppression. The underlying mechanisms are poorly under...
|
Lotta von Boehmer,
Alice Draenert,
Wolfgang Jungraithmayr,
Ilhan Inci,
Schäfer Niklaus,
Annette Boehler,
Markus Hofer,
Rolf Stahel,
Alex Soltermann,
Maries van den Broek,
Walter Weder,
Alexander Knuth
et al.
|
Full-length article
(In Press Corrected Proof)
|
17 November 2011 |
|
A pilot test of a combined tobacco dependence treatment and lung cancer screening program
DOI: 10.1016/j.lungcan.2011.10.011
Abstract: Lung cancer screening with computed tomography has demonstrated a significant reduction in mortality. While these findings are important for the lung cancer research field, the most importan...
|
Amy K. Ferketich,
Gregory A. Otterson,
Mark King,
Nathan Hall,
Kristine K. Browning,
Mary Ellen Wewers
et al.
|
Full-length article
(In Press Corrected Proof)
|
16 November 2011 |